No Data
Even After Rising 13% This Past Week, Landfar Bio-medicine (SZSE:000504) Shareholders Are Still Down 40% Over the Past Three Years
Nanhua Biotech: Report for the third quarter of 2024
Landfar bio-medicine (000504.SZ) released its performance for the first three quarters, with a net loss of 8.4108 million yuan.
Landfar bio-medicine (000504.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
landfar bio-medicine (000504.SZ): a net loss of 8.4108 million yuan in the first three quarters.
On October 30th, Gelonhui reported that Landfar Bio-Medicine (000504.SZ) released its third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 92.4171 million yuan, a year-on-year decrease of 11.78%; the net income attributable to shareholders of the listed company was a loss of 8.4108 million yuan, a year-on-year decrease of 1,828.05%; the net income after deducting non-recurring gains and losses was a loss of 13.2592 million yuan, a year-on-year increase of 14.35%; and the basic earnings per share was -0.0255 yuan per share.
Landfar Bio-medicine Co., Ltd (SZSE:000504) Stock Rockets 37% As Investors Are Less Pessimistic Than Expected
Landfar Bio-Medicine (000504.SZ): Currently no retirement sector business
On September 26th, Landfar Bio-Medicine (000504.SZ) stated on the investor interaction platform that the company currently has no retirement sector business.
There's Reason For Concern Over Landfar Bio-medicine Co., Ltd's (SZSE:000504) Massive 45% Price Jump
No Data
